Kura Oncology (NASDAQ:KURA) Price Target Raised to $36.00 at Wedbush

Kura Oncology (NASDAQ:KURA) had its price objective raised by analysts at Wedbush from $34.00 to $36.00 in a report released on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 316.18% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on KURA. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price target for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Stock Performance

KURA opened at $8.65 on Thursday. The business has a 50 day moving average price of $8.79 and a two-hundred day moving average price of $15.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market capitalization of $672.62 million, a price-to-earnings ratio of -3.67 and a beta of 0.78. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same period last year, the business posted ($0.50) earnings per share. Research analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,255 shares of company stock valued at $100,739. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new position in shares of Kura Oncology during the 2nd quarter valued at about $541,000. AQR Capital Management LLC boosted its holdings in shares of Kura Oncology by 251.5% during the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after buying an additional 58,422 shares during the period. The Manufacturers Life Insurance Company grew its stake in Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after buying an additional 1,976 shares during the last quarter. nVerses Capital LLC bought a new stake in Kura Oncology during the third quarter valued at about $25,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after purchasing an additional 5,788 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.